Company
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to an existing topical antifungal; does not report clinical trial outcomes or comparative efficacy data.
APR 28, 2026 · REGULATORY APPROVAL
U.S. Food and Drug Administration
FDA approval of a generic topical doxepin cream formulation; a regulatory action that confirms manufacturing and bioequivalence standards but does not report clinical trial outcomes.